Ms. Altman was appointed CEO of NeuroDerm in 2019, after serving as the company’s VP Commercial Operations. She has 27 years of experience spanning commercial, business, and global supply chain operations in the pharmaceutical and medical device industries, leading global brands from early development to commercialization.
Since 2000, Ms. Altman has held several positions of increasing responsibility at TEVA, leading the pharma giant’s Global Branded Product Operations and Supply Chain. Ms. Altman was responsible for over 50 different products, managing both marketed and pipeline products across 50 different markets worldwide. Most notably, Ms. Altman led the commercialization process of TEVA’s flagship brand-name product, Copaxone®, for the treatment of multiple sclerosis, from its initial launch to a multi-billion-dollar, global business.
Since then, Ms. Altman has served in various capacities at TEVA, working in global, regional, and local positions in diverse, multi-cultural environments – most recently as VP, Commercial Operations – International markets, where she led regional operational strategy and enhanced commercial and sales operations. She was later appointed Head of Enterprise Risk Management and Business Continuity, leading Teva’s global ERM function and cross-corporate risk community.
Ms. Altman holds a B.Sc. in Industrial Engineering and Management from the Technion – the Israeli Institute of Technology, an MBA from Tel Aviv University, and has attended the Global Leadership Program at INSEAD (Fontainebleau).
Dr. Chiba has served as a member of the Board of Directors and taken over the Chairman of the Board from Mr. Kawakami since April 1st,2019, based on the mission of achieving the final goal to launch NeuroDerm’s proprietary innovative medicines to the patients and maximize the value of projects in close collaboration with NeuroDerm and Mitsubishi Tanabe Pharma Corporation (MTPC) like as “One Company”. He has built up a wide range of career through taking various roles and responsibilities of R&D, CMC and SCM functions for more than 30years in MTPC since he started his career as a pharmaceutical scientist in Pharmaceutical Development Department, Kashima Plant, Mitsubishi Chemical Industries in 1998. He is currently the Managing Director of Mitsubishi Tanabe Pharma Europe (MTPE) to lead the overall MTPE business activities including the European development and commercialization. He has also served as a member of the Board of Directors of MTPE as well as Mitsubishi Tanabe Pharma GmbH (MTPD). In the past, he served as the Vice president of Discovery Formulation Research Laboratory in Research Division, Associate Director of Product Strategy & Planning Department and R&D Reform Department, Vice President/Head of Production Technology Management Department in Production Division and CMC Strategy & Planning Department in CMC Division, Senior Vice President/Head of CMC Division and Production Technology & Supply Chain Management Division. He received a master’s degree in pharmacy from Department of Pharmacy, Tokyo University and a Ph.D. in Pharmaceutical Science from Department of Pharmacy, Tokyo University of Science through the collaboration with Department of Chemical Engineering, Massachusetts Institute of Technology (Prof. Langer’s lab). He also earned MBA from Japan Productivity Organization. He is a member of the Scientific Advisory Board of the Japan Science and Technology Agency (CREST, ERATO).
BSc – Board
Mr. Himizu has served as a member of the Board of Directors since October 2017. He has an extensive career in taking responsibilities in various roles of R&D serving more than 30years at Mitsubishi Tanabe Pharma Corporation (MTPC), the parent company of NeuroDerm.
He is currently the head of NeuroDerm Office, the post-merger integration counterpart at MTPC, collaborating closely with NeuroDerm to maximize their value of projects. In the past, he served as Deputy Division Manager, Sohyaku Innovation Research Division, Translational Research Department Manager, R&D Reform Department Manager and Project Management Department Manager. As taking the lead in several clinical development projects, he was responsible to achieve more than 10 approvals of new drug indications/sustained release formulations in the areas of cardiovascular diseases, CNS diseases and Immune inflammatory diseases.
BSc – Board
Mr. Tanabe serves as the Executive Officer of Product Technology & Supply Chain Management Division, Mitsubishi Tanabe Pharma Corporation. He has almost 30 years of CMC development experience for both low-molecular-weight pharmaceuticals and biopharmaceuticals including vaccine products. He led CMC activities as a project leader or as the Department Head. Mr. Tanabe recently has engaged the corporate management at Mitsubishi Tanabe Pharma Europe and Corporate Strategy Planning Department. Mr. Tanabe holds a BSc in Chemistry from Osaka University.